Extended Data Fig. 5: In vivo efficacy of AZD5582-based combination treatments.
a, Frequencies of human CD45+ AML cells in the recipient spleen with or without treatment are shown. For each category, 91 PDX mice created from 8 AML cases with sensitivity to both AZD5582 and venetoclax, 33 PDX mice created from 4 AML cases with sensitivity to AZD5582 but resistance to venetoclax and 15 PDX mice created from 2 AML cases with resistance to AZD5582 but sensitivity to venetoclax were analyzed. Data are shown as mean + /-s.e.m. Detailed data for each PDX-model mouse is summarized in Supplementary Table 8. b.c, AML cell elimination in (b) femurs and (c) spleens of PDX mice, shown by immunohistochemical staining for human CD45+ (brown) and HE staining. Broken lines indicate blood vessels containing erythrocytes; arrowheads indicate neutrophils; arrows indicate megakaryocytes.
